Empagliflozin-Associated Pancreatitis in the Setting of Hyperglycemic Hyperosmolar Syndrome
Abstract
Abstract Acute pancreatitis is the leading cause of gastrointestinal hospital admissions in the United States [1]. While there are variety of presentations, the majority to not require stay in the intensive care unit. Medication side effect is one large cause of pancreatitis. More recently diabetic agents have been linked to pancreatitis. Here we describe a case of pancreatitis caused by a SGLT-2 Inhibitor, Empagliflozin, and the acceleration into hyperosmolar hypoglycemic syndrome and ICU admission. We hope to provide more information for clinicians detailing the link and outlining the management in cases such as this which do significantly increase inpatient morbidity and mortality.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.